Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 475 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Menopausal Women Clear all
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

NCT00683917
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex 25 mg, Proellex 50 mg, Lupron Depot
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Sarasota, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 24, 2026, 3:18 PM EDT
Terminated Phase 2 Interventional Results available

Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

NCT01251354
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BN83495
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Augusta, Georgia • Minneapolis, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women

NCT00029757
View directory record Official record
Conditions
Menopause, Postmenopause
Interventions
Estrogen
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
35 Years to 75 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2005 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Raising Insulin Sensitivity in Post Menopause

NCT02274571
View directory record Official record
Conditions
Menopause
Interventions
TSEC (Tissue-selective estrogen complexes), Placebo
Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years to 60 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Phase 3 Interventional

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

NCT00172081
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
107
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 24, 2026, 3:18 PM EDT
Not listed Phase 2 Interventional

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

NCT00280930
View directory record Official record
Conditions
Post-Menopausal, Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2007 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Phase 2 Interventional

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

NCT00165204
View directory record Official record
Conditions
Menopause, Postmenopausal Bone Loss, Breast Cancer
Interventions
Tibolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 24, 2026, 3:18 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

How Does Perimenopausal Menorrhagia Affect Women's Quality of Life and Cognitive Function?

NCT06798584
View directory record Official record
Conditions
Iron Deficiency Anemia Treatment, Iron Deficiency, Iron Deficiency (Without Anemia)
Interventions
FeoSol Original Iron Supplement Tablets, 21st Century Gelatin Capsules
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 24, 2026, 3:18 PM EDT
Not yet recruiting Not applicable Interventional

Evaluation of the Effects of Lifestyle Medicine and Mindfulness-based Group Medical Visits on Stress, Microbiome, and Quality of Life in Women Experiencing Perimenopause and Menopause

NCT07619352
View directory record Official record
Conditions
Perimenopause, Menopause
Interventions
Navigating Menopause with a Mindfulness-Based Group Medical Visit
Other
Lead sponsor
Ohio State University
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 3:18 PM EDT
Completed No phase listed Observational

Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

NCT03218085
View directory record Official record
Conditions
HIV/AIDS, Menopause, Inflammation Vagina
Interventions
Tenofovir, Emtricitabine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of a Postbiotic Supplement on Menopausal Symptoms in Premenopausal Women

NCT07570043
View directory record Official record
Conditions
Perimenopause, Menopausal Symptoms, Menopause-Related Quality of Life, Microbiome
Interventions
Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Able Biolabs, LLC
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

NCT04209543
View directory record Official record
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol, Placebo, Progesterone
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
65
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 24, 2026, 3:18 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women

NCT05169840
View directory record Official record
Conditions
Coronary Artery Disease, Genetic Predisposition to Disease
Interventions
Genetic Risk Score for Coronary Artery Disease
Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
40 Years to 60 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

NCT03018366
View directory record Official record
Conditions
Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
Interventions
17beta Estradiol, Transdermal placebo patch, Progesterone, Placebo Pill
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 24, 2026, 3:18 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women

NCT01126801
View directory record Official record
Conditions
Menopausal Depression
Interventions
Estradiol, Placebo control
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

NCT01829919
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate)
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

NCT01732770
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biomarkers in Post-Menopausal Women Receiving Flaxseed

NCT01698294
View directory record Official record
Conditions
No Evidence of Disease
Interventions
Clinical Observation, Flaxseed, Laboratory Biomarker Analysis, Questionnaire Administration
Other · Dietary Supplement
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 24, 2026, 3:18 PM EDT
Recruiting Phase 1 Interventional

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

NCT07401381
View directory record Official record
Conditions
Hormone Receptor Positive Early Breast Cancer
Interventions
US-sourced oral Femara® + Letrozole SIE, EU sourced oral Femara® + Letrozole SIE
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Beverly Hills, California • Margate, Florida • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Not applicable Interventional

Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer

NCT00031811
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms, Osteoporosis
Interventions
raloxifene, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bonafide Sleep Supplement for Menopausal Women With Sleep Complaints

NCT07839312
View directory record Official record
Conditions
Sleep Disturbance
Interventions
S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 3:18 PM EDT
Recruiting Not applicable Interventional

Hemodynamics After Resistance Training

NCT07022340
View directory record Official record
Conditions
Perimenopause
Interventions
Resistance Training Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 24, 2026, 3:18 PM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 24, 2026, 3:18 PM EDT
Recruiting Not applicable Interventional

VALOR: Vaginal Atrophy & Long-term Observation of Recovery

NCT05953090
View directory record Official record
Conditions
Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)
Interventions
7-0940
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Burbank, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 24, 2026, 3:18 PM EDT